Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 20,908

Document Document Title
WO/2015/060650A2
The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide en...  
WO/2015/060650A3
The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide en...  
WO/2015/056713A1
The problem of the present invention is to provide a peptide that functions as a c-Met agonist. The present invention provides a peptide complex formed from two or more peptides that couple with a c-Met protein and a linker that joins th...  
WO/2015/058161A1
Studies of the pathogenic mechanisms underlying human myopathies and muscular dystrophies often require animal models, but models of some human diseases are not yet available. The present invention provides methods to promote the engraft...  
WO/2015/051234A3
Methods and compositions for treating lupus nephritis and muscle atrophy with anti-TWEAK antibodies are provided. Methods that include administering therapeutically effective amounts of anti-TWEAK antibodies to human subjects already rec...  
WO/2015/050160A1
The present invention provides an anti-aging pharmaceutical composition for muscle containing as the active ingredient parathyroid hormone, a parathyroid hormone derivative, or a salt thereof. Preferably the parathyroid hormone derivativ...  
WO/2015/051283A1
Methods for modulating expression of SMN1 and/or SMN2 in cells obtained from subjects having ALS or in subjects having ALS using single stranded oligonucleotides are provided. Methods for treating ALS using single stranded oligonucleotid...  
WO/2015/049630A1
This relates to the use of an IGF-1 mimetic in human therapy. In particular, disclosed herein is the use of an IGF-1 precursor protein, particularly a human IGF-1 precursor protein, comprising the E-peptide for the treatment of Spinal an...  
WO/2015/042685A1
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhi...  
WO/2015/037656A1
 Autophagy-regulating miRNA molecules according to the present invention are formed from base sequences represented by any of SEQ ID NO: 1-203 in the sequence listing. These miRNA molecules were identified using an miRNA screening meth...  
WO/2015/037659A1
 An aqueous solution formulation containing compound (I) can be manufactured by performing the following steps: a first step in which a solution is prepared by dissolving, in an organic solvent, a compound represented by formula (I) or...  
WO/2015/037001A1
The present invention providesamethod for inducing glucose uptake in a muscle cell by inhibiting Trim32 protein in the cell and to a method for inducing glucose uptake in a muscle cell, by increasing the abundance of plakoglobin protein ...  
WO/2015/035460A1
An antisense oligonucleotide of 10 to 50 nucleotides comprising a targeting sequence complementary to a region near or within intron 6, intron 7, or exon 8 of the Survival Motor Neuron 2 (SMN2) gene pre-mRNA.  
WO/2015/037720A1
 Provided is a muscle repair promoter intended for use in a target of which rapid absorption of protein is required, and containing as an effective ingredient a lactoprotein mixture that includes casein protein and whey protein, wherei...  
WO/2015/032812A1
The invention relates to a composition for controlling or preventing locomotor disorders, especially locomotor disorders that may affect mammals including humans or pets or recreational animals, especially cats, dogs and horses. The comp...  
WO/2015/035171A1
The present invention provides methods for treating muscle atrophy by administering a PPARδ agonist.  
WO/2015/022927A1
The purpose of the present invention is to provide a novel AMP-activated protein kinase (AMPK) activator with a high safety. An AMPK activator that comprises a liver hydrolysate as an active ingredient.  
WO/2015/022386A1
The present invention relates to a pharmaceutical combination product for use in a method for preventing or treating muscular dystrophy, particularly Duchenne muscular dystrophy or Becker muscular dystrophy. The combination product compr...  
WO/2015/023939A1
Provided herein are compositions and methods for increasing Frataxin (FXN) expression. Compositions and methods for treating Friedrich's ataxia are also provided.  
WO/2015/022658A3
The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding mole...  
WO/2015/018913A1
Use of a ketone body and a ketone body ester for preserving glycogen and/or protein, thereby reducing muscle breakdown and improving endurance during exercise and promoting muscle recovery following exercise. Also for retarding muscle wa...  
WO/2015/018356A1
The present invention discloses a diarylhydantoin derivative, and preparation method, pharmaceutical composition, and application thereof. The present invention provides a diarylhydantoin derivative as represented by formula I, a pharmac...  
WO/2015/017589A1
The present invention provides a compound of formula IA or a pharmaceutically acceptable salt thereof; 5 (IA) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a c...  
WO/2015/007730A1
The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds ...  
WO/2015/006863A1
Improved processes for extracting polyphenols and/or flavonoids from citrus peels comprising: 1) heating a ground peel to form a pre-treated, ground peel; and 2) extracting the compounds of interest from the pre-treated, ground peel usin...  
WO/2015/009952A1
The invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a ...  
WO/2015/008836A1
 An agent for preventing muscle atrophy and/or promoting muscle synthesis containing, as active ingredients, a basic protein fraction derived from milk and/or a resolvent of a basic protein fraction derived from milk, and whey protein ...  
WO/2015/004485A1
The present invention relates to therapeutic compounds useful for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia). The compounds have the structural formula I shown ...  
WO/2015/004609A3
A method of treating injured tendons in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of placenta- derived adherent stromal cells.  
WO/2015/001995A1
 Provided is a rocuronium preparation that makes it possible to suppress vascular pain. This rocuronium preparation is characterized by containing rocuronium and a buffer and having titratable acidity of 100 mEq or less. The buffer may...  
WO/2014/208354A1
The present invention relates to a pharmaceutical composition for treatment or prophylaxis of inflammatory diseases. A pharmaceutical composition according to the present invention contains, as an active ingredient, a compound that is se...  
WO/2014/210369A3
We provide methods and kits to reverse neuromuscular block caused by a cysteine-inactivated neuromuscular blocking drug, comprising administering to said subject a combination of a cysteine-like agent and an acetylcholinesterase inhibito...  
WO/2014/205045A1
Disclosed herein are methods of improving muscular health, such as enhancing muscle regeneration, maintenance, or repair. In some examples, the method includes administering to the subject an effective amount of an agent capable of incre...  
WO/2014/203518A1
Disclosed are double-stranded antisense nucleic acid complexes that can efficiently alter the processing of RNA in a cell via an antisense effect, and methods for using the same. One method comprises contacting with the cell a double-str...  
WO/2014/204090A1
The present invention discloses a composition comprising a filler and Botulinum toxin for alleviating skin wrinkles or aging or treating neuromuscular diseases. The composition according to the present invention resolves neuromuscular di...  
WO/2014/199935A1
[Problem] To provide a prophylactic or treatment agent for body weight increase or obesity being a side effect of antidepressants, antipsychotic drugs, analgesics, or treatment agents for fibromyalgia. [Solution] A prophylactic or treatm...  
WO/2014/199171A1
The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy.  
WO/2014/199960A1
The present invention provides a novel compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which is useful for prophylaxis or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive imp...  
WO/2014/198164A1
The present invention relates to the field of medicinal chemistry, specifically to a cis-benzylisoquinoline compound (I), a preparation method therefor, a pharmaceutical preparation containing said compound and medical uses thereof. The ...  
WO/2014/199315A1
The present invention relates to novel derivatives of hydrophilic bioactive peptides which have been modified by introducing a lipophilic substituent through esterification of the free carboxylic group(s) of the peptide with an aliphatic...  
WO/2014/200075A1
Provided are 4-alkynyl imidazole derivatives represented by general formula (I) and pharmacologically permissible salts thereof. The derivatives have excellent EP4 receptor antagonist effects and are useful as medicines for treating dise...  
WO/2014/196644A1
The inventors perfected the present invention as a result of a study into IK1 channel activators and a confirmation that a benzothiophene compound exhibits efficacy against visceral pain, inflammatory pain, osteoarthritic pain, neuropath...  
WO/2014/190866A1
Provided is a muscle stem cell in vitro culture method. A muscle stem cell is cultivated in vitro by using a cell culture medium of a cell factor added with a blood cell or a conditioned medium of the blood cell. Also provided are a cult...  
WO/2014/189634A1
The present invention provides, among other things, methods of treating a muscular dystrophy including administering to a subject suffering from or susceptible to a muscular dystrophy an angiotensin (1-7) peptide. The present invention i...  
WO/2014/188198A1
The present invention relates to a method of treating adverse fat accumulation and related conditions with very low doses of tacrolimus or a close structural analogue thereof. In particular this invention relates to treating adverse fat ...  
WO/2014/190250A1
Methods for ameliorating and/or treating the symptoms associated with dystrophic diseases such as Duchenne muscular dystrophy (DMD) in a subject comprising administering to a subject a pharmaceutical composition comprising a nitric oxide...  
WO/2014/188214A1
A topical pharmaceutical composition for use in alleviating or reversing a clinical symptom selected from rigidity, stiffness, loss of mobility, loss of flexibility and swelling in a part or region of the body is described, wherein the c...  
WO/2014/188730A1
Provided is an agent for oral ingestion whereby human motility function can be improved. A motility function-improving agent that comprises lutein and a milk component as active ingredients, said motility function-improving agent being u...  
WO/2014/189475A1
The invention relates to a composition formed for treating the muscle weakness and the loss of muscle mass following the chronic stroke and coma.  
WO/2014/189071A1
 Provided are stem cells for transplantation composed of MSCs capable of overexpression of IL-10 as means for providing: MSCs for transplantation having improved take ratio and cell survivability after transplantation, and having high ...  

Matches 201 - 250 out of 20,908